Genetic alterations associated with prostate cancer (PCa) may be identified by sequencing metastatic tumour genomes to identify molecular markers at this lethal stage of disease. Previously, we characterized somatic alterations in metastatic tumours in the methylcytosine dioxygenase ten-eleven translocation 2 (TET2), which is altered in 5-15% of myeloid, kidney, colon and PCas. Genome-wide association studies previously identified non-coding risk variants associated with PCa and melanoma. We perform fine-mapping of PCa risk across TET2 using genotypes from the PEGASUS case-control cohort and identify six new risk variants in introns 1 and 2. Oligonucleotides containing two risk variants are bound by the transcription factor octamer-binding protein 1 (Oct1/POU2F1) and TET2 and Oct1 expression are positively correlated in prostate tumours. TET2 is expressed in normal prostate tissue and reduced in a subset of tumours from the Cancer Genome Atlas (TCGA). Small interfering RNA-mediated TET2 knockdown (KD) increases LNCaP cell proliferation, migration and wound healing, verifying loss drives a cancer phenotype. Endogenous TET2 bound the androgen receptor (AR) and AR-coactivator proteins in LNCaP cell extracts, and TET2 KD increases prostate-specific antigen (KLK3/PSA) expression. Published data reveal TET2 binding sites and hydroxymethylcytosine proximal to KLK3. A gene co-expression network identified using TCGA prostate tumour RNA-sequencing identifies co-regulated cancer genes associated with 2-oxoglutarate (2-OG) and succinate metabolism, including TET2, lysine demethylase (KDM) KDM6A, BRCA1-associated BAP1, and citric acid cycle enzymes IDH1/2, SDHA/B, and FH. The co-expression signature is conserved across 31 TCGA cancers suggesting a putative role for TET2 as an energy sensor (of 2-OG) that modifies aspects of androgen-AR signalling. Decreased TET2 mRNA expression in TCGA PCa tumours is strongly associated with reduced patient survival, indicating reduced expression in tumours may be an informative biomarker of disease progression and perhaps metastatic disease.
INTRODUCTION
Metastatic prostate cancer (mPCa) is poorly controlled using existing therapies and is responsible for more than 258 000 deaths worldwide each year. 1 Molecular markers that distinguish indolent from aggressive disease and identify therapeutic targets may improve patient stratification for precision medicine. Genetic analysis to determine the precise molecular chronology of causal alterations arising during progression of PCa to castration-resistant and metastatic disease has been difficult, in part, because of the very high heterogeneity of primary adenocarcinomas and a paucity of metastatic tumours.
Frequent somatic ten-eleven translocation 2 (TET2) alterations have been observed in myeloproliferative disorders (MPDs), 2, 3 mastocytosis and polycythemia vera, and in fewer but significant numbers of epithelial-derived tumours, [4] [5] [6] [7] [8] [9] [10] [11] including PCa. [9] [10] [11] Germline TET2 variants are associated with an increased risk of prostate 12, 13 and endometrial 7 cancers, and melanoma. 8 Thus, germline and somatic alterations implicate TET2 as a cancer gene in MPDs and epithelial cancers.
Previously, we sequenced the exomes of five distinct metastatic tumours and healthy tissue from a patient with PCa and identified four cancer gene alterations, 11 an inherited breast cancer-1 (BRCA1) truncation (p.E23fs*) associated with PCa, 14 a somatic deletion giving rise to a fusion of the transmembrane protease TMPRSS2 and the transcription factor (TF) ERG, 15 a somatic missense substitution in a bromodomain of PBRM1, 16 and a somatic TET2 missense substitution (p.P562A). Significantly, the TET2 substitution was observed in all 11 mPCa tumours but not in the primary tumour, suggesting altered TET2 may provide a survival benefit distinct from altered BRCA1, TMPRSS2-ERG and PBRM1.
Analysis of mPCa tumours from additional patients showed TET2 alterations in 13/30 tumours 11, 18 and we identified a frameshift truncation (p.T229fs*) in DU145, an androgen-independent cell line derived from an mPCa brain tumour. Thus, the presence of germline and somatic TET2 alterations suggests an altered TET2 may be associated with progression in a subset of PCa patients.
In this study, we identify six new PCa risk variants in TET2 introns 1 and 2, and show TET2 physically interacts with the androgen receptor (AR) and AR-coactivators PSPC1, NONO and SFPQ. TET2 loss drives a cancer phenotype by increasing LNCaP prostate cell proliferation and invasion, and KLK3/PSA expression. Network analysis reveals TET2-AR interacts with proteins that are frequently altered across cancers. We identify a TET2-associated co-expression signature in the Cancer Genome Atlas (TCGA) in PCa tumours that includes cancer genes encoding functions related to 2-oxoglutarate (2-OG) and succinate metabolism. The signature is observed across cancers indicating frequent dis-regulation of 2-OG and succinate metabolism in cancer.
RESULTS

PCa risk variants
We genotyped 47 TET2 locus single nucleotide polymorphisms (SNPs) in 4838 cases and 3053 controls in the PEGASUS cohort as part of the Cancer Genetic Markers of Susceptibility Study (National Cancer Institute, Bethesda, MD) (Supplementary Table S1 ). Seven, including the previously reported promoter variant, rs7679673 12 and six new SNPs in introns 1 and 2, were found to be significantly associated with increased PCa risk (P ⩽ 10 À 4 ) (Table 1, Figure 1a ). SNP rs7679673 retained the highest association with risk (P = 1.6 × 10 ) followed by rs1015521 in intron 2 (P = 8.6 × 10
). Two SNPs in intron 1, rs17508261 and rs6825684, had a slightly more protective homozygous odds ratio (0.68 and 0.69, respectively) than rs7679673 (0.72).
We examined TF binding to oligonucleotides containing the new risk SNPs by electrophoretic mobility shift assay and observed protein binding to oligonucleotide probes containing rs17508261-C and rs7655890-G/T in LNCaP and PC3 cell line nuclear extracts (Figure 1b) . TF binding was confirmed in repeat experiments and additional proteins interacting with these oligonucleotides in kidney 293, cervical HeLa and breast MCF7 cells were observed but not further examined (Figure 1c) . In silico analysis of TF-binding sites revealed that rs17508261 was located in an Oct1/ POU2F1 19 -binding DNA sequence motif (Supplementary Figure S1 ). Supershift analysis with TF-specific antibodies showed altered migration or reduced binding to labelled oligonucleotides containing rs17508261-C and rs7655890-T in the presence of an anti-Oct1 antibody whereas no supershift was observed with other TF antibodies examined. The SNP genotypes indicate rs17508261-C and rs7655890-T are risk and protective alleles, respectively (Figure 1e ; Supplementary Tables S1). Thus, rs17508261-C may be a functionally significant PCa risk variant due to Oct1 binding.
Three risk variants, rs7679673-A, rs17508261-C and rs7655890-G, were in linkage disequilibrium in a rare risk haplotype (Supplementary Table S2 ). To test the effect of these alleles on TET2 expression, we genotyped rs7679673, rs17508261 and rs7655890 in 11 PCa cell lines and examined normalized TET2 expression. We found no association between the SNP genotype and TET2a mRNA expression (Supplementary Figure S2) , but did observe that 4 of 11 (36%) PCa cell lines, DU145, PC3, PWR-1E and VCaP, exhibited significantly reduced TET2 expression (Figure 1f ; Supplementary Tables S3). TET2 expression in DU145 cells may be reduced due to a p.T229fs* mutation.
11
To analyse the relationship between TET2 and Oct1 expression, we measured the mRNA levels of TET2 and Oct1 in 12 PCa cell lines using real-time, quantitative PCR (Supplementary Figure S3) . Pearson correlation showed a positive but not significant correlation between TET2 and Oct1 expression. We examined TET2 and Oct1 expression in an independent dataset, TCGA PCa tumours, using tumour RNA sequencing and observed a positive Pearson correlation indicating co-expression (P = 0.0097, Supplementary Figure S3 ). Thus, risk SNPs within the TET2 transcriptional locus conclusively identify TET2 as the PCa risk gene on chr 4q24. The significance of Oct1-binding to TET2 risk variants relative to Oct1's described roles in cancer stem cells and the cell cycle remains to be determined. 19, 20 Somatic alterations in epithelial cancers The spectrum of somatic mutations indicates that TET2 functions as a tumour suppressor in MPD, 2,3 so we assembled 97 somatic mutations observed in epithelial tumours from published studies, [4] [5] [6] [7] [8] [9] [10] [11] TCGA and the Catalogue of Somatic Mutations in Cancer (COSMIC) (Supplementary Figure S4a; Supplementary Table S5 ). Forty-nine (51%) alterations were predicted to be loss of function, indicating that TET2 potentially functions as a tumour suppressor in epithelial cancer. Additional experimental data are required to confirm whether all alterations have a similar effect on function. Recent next generation sequencing-molecular analyses of PCa [9] [10] [11] 21, 22 available through the cBioPortal for Cancer Genomics 23 reveal a low but significant number of somatic TET2 alterations (Supplementary Figure S4b) . We were able to assess TET2 status in 246 primary adenocarcinomas and 117 metastatic tumours and observed a significantly greater number of somatic alterations in metastatic as compared to primary tumours (23 Figure S4c) . 5, 11, 24 Reduced expression in advanced, lethal PCa Reduced TET2 expression in MPD is a predictor of disease progression and poor overall survival. 25, 26 We re-examined normalized mRNA expression in a recent PCa study 9 of 29 matched normal adjacent tissue (NAT) samples, 131 primary tumours and 19 metastatic tumours. Expression decreased when comparing the NAT with primary tumours, though not significantly, but was significant when comparing primary with TET2 defects in prostate cancermetastatic tumours (P = 0.01; Figure 2a ). Expression was reduced in 145 primary and metastatic tumours with a high (⩾ 7) versus low (o 7) combined Gleason score (P = 0.006; Figure 2b ). There was no association between reduced TET2 expression and tumour stage (P = 0.44, data not shown). We evaluated the normalized TET2 mRNA expression in tumours compared to the NAT using a Z-score ⩽ -2.0 criteria, and identified 7 of 131 (5.3%) primary tumours and 7 of 19 (36.8%) metastatic tumours with significantly reduced expression ('Low') as compared to the average (Figure 2c ). Reduced expression in 3 of 14 (21%) TET2-low tumours were attributable to copy number variation loss; gene sequencing data were not available. 9 Thus, unknown additional mechanism(s) reduce mRNA expression in the majority of tumours. Retrospective Kaplan-Meier analysis revealed shortened disease-free survival (DFS) in the seven patients with TET2-low primary tumours as compared with 123 patients with tumours displaying average TET2 expression (P = 6.4 ×10
; Figure 2d ). Thus, reduced TET2 mRNA expression in tumours is significantly associated with a lethal subtype of PCa.
We confirmed by real time-polymerase chain reaction (RT-PCR) and western blot (WB) using a previously described monoclonal antibody 27 that TET2a (NM_001127208; 2002 amino acids [aa]) was highly expressed in prostate tissue, tumours and cell lines. TET2a and TET2b (NM_017628; 1165 aa) were both expressed in prostate samples and are transcribed 810 base pairs apart (HG19) (Figures 1a and 2e-h; Supplementary Table S4 ). All samples exhibited alternative splicing of the TET2a untranslated exon 2 (TET2a-deleted exon 2 [TET2a-delex2]).
Immunohistochemistry of serial sections of a PCa tissue microarray revealed TET2 and 5-hydroxymethylcytosine (hmC) were depleted in tumours as compared to the NAT (Supplementary Figure S5) . We observed TET2-and hmC- positive epithelial cells and TET2-negative, hmC-positive stromal cells. The stromal cells exhibiting 5-hmC staining suggests TET1 or TET3 may be active. TET2 was observed in the cytoplasm, indicating likely cytoplasmic-to-nuclear shuttling similar to that previously observed for several TET2-AR nexus proteins described below, including the AR, BAP1 and the E1A binding protein p300 (EP300).
TET2 loss is associated with cancer progression We identified two small interfering RNAs (siRNAs) (Figure 1a ; Supplementary Table S3) that reduced TET2 protein levels by 460% in both LNCaP and DU145 cells, comparable to the reduction observed in tumours. Treatment of LNCaP cells with siRNA siTET2-1 reduced TET2 protein levels by 63% (37 ± 6 and 100 ± 27, respectively) after 24 h as compared with untreated cells (Figures 3a-c) [normalized mRNA expression was reduced by 41% as compared with untreated LNCaP (18 ± 1 and 30 ± 1, respectively)]. Treatment with a non-targeting scrambled siRNA (scRNA) did not significantly alter TET2 expression.
In vitro, TET2 knockdown (KD) after siTET2-1 treatment Figure S6) . Thus, reduced TET2 mRNA and protein increase in vitro prostate cell proliferation, wound healing and invasion; characteristics favouring cancer progression and metastasis.
TET2 binding proteins in HEK293T cells
We purified TET2 binding proteins from human embryonic kidney 293T (HEK293T) cells using exogenous 3x FLAG-tagged TET2 (FLAG-TET2) and affinity purification and mass spectrometry (Supplementary Tables S6 and S7 ). We identified the acetylglucosamine transferase OGT, which catalyzes the transfer of acetylglucosamine to histones. 28, 29 Putative TET2 interactors were enriched in proteins with RNA and chromatin binding functions. Several AR binding proteins were detected, including PSPC1, 30 filamin A 31 and KDM6A. 10, 32, 33 Additionally, AR-coactivator proteins, the octamer-binding NONO and the splicing factor SFPQ were enriched in TET2 affinity purifications as compared to the controls (Supplementary Figure S7) . PSPC1, NONO and SFPQ bind the AR to regulate transcription; 34 however, AR peptides were not observed. Using forward and reverse immunoprecipitation (IP), we confirmed TET2 interactions with PSPC1, OGT and NONO in HEK293T cells.
TET2-AR binding in prostate cells
We confirmed the interactions between endogenous TET2 and OGT, PSPC1, NONO and SFPQ in LNCaP cells using IP with the appropriate antibodies (Figure 4a ). Reciprocal IP of endogenous TET2 with anti-TET2 antibody confirmed the interactions (Figure 4b ). Anti-AR antibody precipitated TET2, NONO and OGT in LNCaP cells (Figure 4c ). Additional IPs in HEK293T cells failed to confirm a TET2-AR interaction (data not shown), suggesting it may be specific to prostate cells.
SFPQ and NONO regulate AR-mediated gene expression by recruiting the transcription regulator SIN3A. SIN3A was detected by WB after IP with anti-AR antibodies ( Figure 4c) ; however, we did not detect a TET2-SIN3A interaction (data not shown). Treatment of cells with dihydrotestosterone (DHT) followed by IP with anti-AR antibodies, and WB with anti-TET2 or anti-SFPQ antibodies showed that interactions in the presence of DHT are slightly (SFPQ) or completely reduced (TET2) when DHT is removed (Figure 4d ). Experiments were independently replicated and not due to a DHT effect on protein in the lysates (data not shown). Thus, a DHT-sensitive, SIN3A-independent, TET2-AR complex is observed in LNCaP cells.
TET2 loss alters expression of genes associated with PCa A TET2-AR interaction suggests a potential role in regulating the expression of genes associated with PCa, possibly through hmC formation. [25] [26] [27] We examined the expression of 53 genes in LNCaP cells after TET2 KD by siTET2-1 using quantitative PCR to determine whether the expression of genes known to be responsive to androgen 35 or genes encoding AR pathway proteins (AR signalling array, Bio-Rad, Hercules, CA, USA) are altered, either of which could alter androgen signalling. The expression of 24 genes were excluded due to significant differences in expression between untreated and scRNA-treated cells (two-tailed T-test Po 0.05), leaving 29 assays in the final analysis. Of these, 12 genes had a significant expression change (P-value o0.05 and/or |fold change| of at least 1.1) (Supplementary Table S8 ). Comparing gene expression between scRNA and siTET2-1 treated cells, TET2 expression was the most significantly reduced, by 1.7 fold (P = 1.9 × 10 -7 ). The expression of six genes was increased after TET2 KD, including KLK3/PSA, 36 hydroxyprostaglandin dehydrogenase HPGD and a centromeric nucleosome-associated protein CENPN. The expression of five additional genes was decreased, including an extracellular signal-regulated kinase MAP2K1, the glycogen synthase kinase GSK3B and the GSK3B-complex protein beta-catenin (CTNNB1).
We confirmed the effect of TET2 KD using a second independent siRNA (siTET2-4) recently described by Takayama et al 37 ( Figure 1a ; Supplementary Table S3 ). We performed three independent treatments of LNCaP cells with siTET2-4 or a GC-matched scRNA control in the absence and presence of DHT. Analysis of quantitative WBs reveal a 52% reduction of TET2 protein compared to scRNA treated cells, similar to the KD achieved using siTET2-1 (Figure 5a ). Unfortunately, a key transfection reagent (siGene, Promega, Japan) was not available to obtain a more effective KD similar to that achieved by Takayama et al. 37 Comparing scRNA-treated cells without DHT to scRNA-treated cells with DHT showed DHT treatment decreased TET2 protein by 33%, confirming previous observations. 37 PSA protein expression was significantly increased (Po0.05; Figure 5b ), confirming the gene expression results (Supplementary  Table S8 ) are correlated with increased protein using two distinct siRNAs targeting TET2. DHT treatment further increased PSA as expected independent of TET2 status.
The expression changes after TET2 KD indicate TET2 may regulate the expression of a subset of androgen-responsive genes. 35 We investigated whether there were TET2 binding sites and hmC proximal to genes with expression changes in Supplementary Table S8 using recently published chromatin IP-sequencing data from LNCaP cells. 37 TET2 binding sites were identified near each gene examined that were accompanied in a more regional genomic context by hmC and methylcytosine (mC) in LNCaP cells. AR binding sites were observed near these genes in sequencing data from DHT-treated prostate cell line, BicR (Supplementary Figure S8, Supplementary Table S9 ). Thus, TET2 KD increases the expression of PSA, an androgen-AR responsive biomarker, in the same direction as DHT treatment, indicating TET2 has a role in regulating the expression of at least a subset of androgen-AR responsive genes (Figure 5c ). Figure S9) and published protein-protein interactions reveal a 'nexus' of interacting cancer gene products (cancer proteins) with diverse functions: epigenetic (left), basal transcription (middle) and 'output' to mRNA splicing and the cell cycle (right) ( Figure 6 , Table 2 and Supplementary Table S10 ). The nexus includes the oncogenic proteins AR and cyclin D1, and multiple tumour suppressors associated with DNA and RNA transcription (Figure 6b ). Cancer proteins in multiple signalling pathways converge on the nexus, including androgen signalling (AR, 10,38,39 KDM6A, 10,32,33 TET2), DNA repair (BAP1 10, 40, 41 ), insulin signalling (OGT) and oxygen sensing (Figure 6c ). The distribution of somatic alterations in a recent PCa study 10 indicates the nexus (g and h) transwell invasion; P-value, two-tailed T-test. Gross cell morphology appears unchanged after the invasion assay. Untd, untreated; scRNA treatment; siTET2, siTET2-1 treatment; size bar, 100 μm; error bars, mean ± s.d. All experiments were performed in triplicate using 40 nM siTET2-1. TET2 antibody: MAb-179-050, Diagenode, Denville, NJ, USA.
is targeted by largely mutually distinct alterations across nexus genes in a majority (72%) of tumours, most frequently by altered AR and nuclear receptor coactivator 2 (NCOA2) (Supplementary Figure S9e) . Core nexus proteins physically interact with additional cancer proteins as identified by the COSMIC Cancer Gene Census (Figure 6d ). We examined tumour gene co-expression networks based on RNA-sequencing from tumours for TCGA PCa tumours and 30 additional cancers to identify transcriptional modules correlated with TET2. Similar analyses have identified the transcriptional responses of cells to changing conditions and identified co-regulated interacting proteins to provide mechanistic insight underlying complex cellular processes. 42, 43 The analysis confirmed the inversely correlated expression in PCa tumours between TET2 and KLK3 (as observed above), CTNNB1, GSK3B and the cyclic-AMP dependent kinase PRKACB, as we observed in LNCaP cells after TET2 KD (Figure 6e,  Supplementary Figure S10a) . We did not observe co-expression between TET2 and the majority of androgen-AR genes by the analysis similar to our experimental results after TET2 KD in LNCaP cells, suggesting a likely distinct rather than general function for TET2 in androgen-AR signalling.
The primary role of TET2 is to catalyze hmC formation from mC in DNA. TET2 binds 2-OG, O 2 , Fe2+ and zinc as cofactors and produces succinate, potentially indicating a role for TET2 as an oxygen and redox-sensitive energy (metabolite) sensor. 44, 45 We examined the co-expression of genes encoding TET2-AR nexus proteins and proteins associated with 2-OG and succinate metabolism (citric acid cycle enzymes 46 ) and observed a robust signal (Figure 6f, Supplementary Figure S10b) . The expression of genes encoding enzymes producing 2-OG (IDH1 and IDH2 47 ) are inversely correlated with the expression of genes encoding 2-OG consuming enzymes (TET1-3 and KDM6A). This transcriptional module is likely designed to tightly regulate and maintain 2-OG/ succinate levels.
Genes co-expressed with TET2 encode additional TET-family enzymes TET1 and TET3, a large number of KDMs, and the oxygen (O 2 ) sensing components von Hippel-Lindau (VHL), 46 HIF1, ARNT and EGLN1 (Supplementary Figure S11) . The O 2 sensing components of the co-expression network likely reflect the regulation of oxygen levels by TET-enzymes (O 2 consuming dioxygenases) and hypoxia-responsive proteins such as HIF1 and ARNT. Significantly, the co-expression network comprised of TET2-AR nexus components and genes encoding 2-OG/succinate metabolizing enzymes that is observed in PCa is observed in all 31 TCGA cancers (Supplementary Figure S10c) indicating a conserved and frequently dis-regulated network across cancers.
DISCUSSION
This study implicates TET2 as a tumour suppressor in PCa that is altered by multiple mechanisms: germline non-coding risk SNPs and rare missense substitutions; 11 somatic sequence changes and copy number variation (primarily loss); and reduced mRNA expression in tumours. The genetic complexity of TET2 alterations in PCa requires that multiple approaches be applied to understand causality to disease, which we have done using fine mapping of PCa risk, identification of binding proteins (AR), experimental TET2 KD combined with cell-based and expression assays (PSA), and computational mining of protein interactions and tumour gene expression datasets.
Fine mapping revealed six SNPs in introns 1 and 2 that are significantly associated with PCa in the PEGASUS cohort, supporting TET2 as the causal gene associated with the promoter risk SNP rs7679673. 12 Somatic alterations in 6% of primary and 20% of metastatic tumours, reduced mRNA expression in a subset of tumours, and experimental evidence that TET2 KD increases LNCaP cell proliferation and invasion indicate TET2 is a tumour suppressor in PCa. TET2 may have been overlooked as a PCa gene until this study because diverse mechanisms alter TET2 during disease progression and somatic copy number variation appears to be more frequent in less-studied metastatic PCa disease.
TET2 catalyzes hmC formation 45 and future studies will examine global gene expression and the role of hmC in androgen-AR signalling. DNA hmC is catalyzed at developmentally associated enhancers 48 that may mediate gene expression by a recently described genomic looping mechanism 49 linked to the synthesis of hmC-modified RNA.
50 TET2 alteration or loss in cancer may disrupt these genomic arrangements to dysregulate gene expression.
A role for TET2 in androgen-AR signalling is supported by the identification of TET2 interaction with the AR and AR-transcriptional co-activators PSPC1, NONO and SFPQ by affinity chromatographymass spectrometry and IP. Increased KLK3/PSA mRNA and protein expression in LNCaP cells after treatment with two different siRNAs targeting TET2, and anti-correlated expression in TCGA PCa tumours by RNA next-generation sequencing, confirms a role for TET2 in regulating PSA expression. Down-regulation of TET2 by DHT is in agreement with recent observations 37 and indicates complex feedback mechanisms. The combination of an enzyme activity dependent on 2-OG and co-expression with 2-OG associated gene products indicates TET2 is an energy sensor in TET2 defects in prostate cancera position to integrate 2-OG levels with androgen signals. We propose a quite reasonable hypothesis that TET2 modifies androgen-AR signalling by the synthesis of hmC that influences gene expression based on the metabolic state (2-OG, succinate, oxygen, iron and zinc) of the cell. Experiments are planned to examine the underlying mechanism(s).
A 2-OG co-expression module highly enriched in cancer proteins indicates the transcriptional network is frequently targeted for disregulation by both germline (BAP1, fumarate hydratase (FH), neurofibromin 1 (NF1), succinate dehydrogenases (SDHA, SDHB), and VHL) 46 and somatic mutations (AR, IDH2, 47 KDM6A and, TET2). The mutations that converge on the TET2-AR nexus and TET2 coexpression network indicate tumours that share a common defect associated with 2-OG/succinate metabolism.
We defined a nexus of interacting cancer proteins with functions relevant to cancer, enriched in proteins encoded by X-chromosome loci and single copy in males, that indicates additional epigenetic modifications are likely involved in androgen-AR signalling. Epigenetic modifications with varying half-lives would provide a mechanism to encode upstream pathway signals for short-and long-term regulation of cellular processes (gene expression). The nexus is enriched in enzymes that alter histones, DNA and RNA, indicating the histone code 51, 52 should be expanded to incorporate TET enzyme-catalyzed nucleic acid modifications.
TET2 KD increases the proliferation of androgen-dependent LNCaP and androgen-independent DU145 cells, supporting that TET2 functions downstream in the androgen-dependency pathway. Thus, therapy targeting TET2 loss may be effective in PCa with upstream AR alterations. Reduced TET2 expression is more prevalent in tumours that have progressed to metastatic disease and have a higher Gleason score, and is associated with significantly reduced DFS in PCa similar to MPDs. [25] [26] [27] 53 These results complement those of Takayama et al. 37 who found that high expression of miR-29b targets TET2 and predicts poor outcome. Decreased expression of miR-29b increased TET2 expression and reduced tumour growth in an animal model of PCa. Thus, reduced TET2 expression in prostate tumours may be an informative biomarker to identify patients likely to progress to metastatic disease. . Black line, interactions, this study; blue, oncogene; orange, tumour suppressor; grey, uncertain; white, not frequently altered in cancer. Co-expressed androgen-AR genes (e) and 2-OG/succinate-associated genes (f) whose expression is anti-correlated (red dots) or correlated (blue dots) with TET2 by Pearson correlation in TCGA PAD tumours based on RNA-sequencing available through the cBioPortal (Broad Institute, Cambridge, MA). A gene-gene expression correlation is indicated by a circle if the Pearson correlation P-valueo0.01; the coloured scoring index is included in Supplementary Figure S10 ; the gene order is based on a hierarchical clustering method.
TET2 defects in prostate cancer 
Cell culture and transfection
LNCaP cells were cultured in RPMI 1640 (Life Technologies) with 10% fetal bovine serum. In experiments examining effects of DHT, charcoal stripped FBS (Life Technologies) was substituted. Cells (2 × 10 5 ) were seeded into six-well plates and grown to 70-80% confluency before treatment with scRNA and siTET2-1 and transfection reagent (Santa Cruz Biotechnology, Dallas, TX, USA). Lipofectamine 3000 (Life Technologies) was used for siTET2-4 transfections. Cell-based assays are in the Supplementary Materials and Methods. HEK293T cells were cultured to~60% confluency in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (Clontech, Mountain View, CA, USA) and 100 μg/ml penicillin/streptomycin. Cells were transfected with a construct expressing an N-terminal 3x-FLAG-TET2 using Fugene HD (Roche, Indianapolis, IN, USA) and were grown for an additional 72 h in a 5% CO 2 /95% air-humidified incubator at 37°C.
Affinity purification 3x-FLAG-TET2 was purified using a mouse anti-FLAG M2 monoclonal antibody covalently bound to agarose beads (Sigma-Aldrich, St Louis, MO, USA). The eluate was analysed by nanoflow reverse-phase liquid chromatography-tandem mass spectrometry. Additional details are included in the Supplementary Materials and Methods.
Gene expression
TET2a and TET2a-delex2 expression were measured using FAM-labelled Hs00969056 and Hs01061044, respectively (Life Technologies). TET2b expression measurements utilized TET2b-specific exon 3 primers and a FAM-labelled probe (Supplementary Table S3 ). Expression was normalized to HPRT1 (Hs02800695, Life Technologies) using the delta C T method to determine relative gene expression based on a human universal control of 100% (Clontech). cDNA from TET2 KD cells was prepared using a Cells-to-Ct kit (Ambion/Life Technologies, Foster City, CA, USA). Assays for individual genes (Applied Biosystems, Waltham, MA, USA) and the AR array (#10047227, Bio-Rad) were purchased. Expression was normalized by β-actin (Applied Biosystems) or the geometric mean of HPRT1 and GAPDH (AR array). See the Supplementary Materials and Methods for details about the co-expression analyses.
Clinical impact of TET2 loss Samples included 29 NAT, 131 primary tumours and 19 metastatic tumours. 9 Stage and grade were available for 14 and 18 metastatic tumours, respectively.
Statistical analysis
TET2 expression differences between clinical groups was assessed using a two-tailed Wilcoxon rank sum test, TET2 isoform and gene panel expression by a two-tailed T-test, and DFS by a log-rank test, all using R (www.R-project.org).
